UBS Maintains Buy on C4 Therapeutics, Lowers Price Target to $26
UBS analyst Colin Bristow maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and lowers the price target from $64 to $26.
BMO Capital Maintains Outperform Rating for C4 Therapeutics, Lowers Price Target To $20
BMO Capital has decided to maintain its Outperform rating of C4 Therapeutics (NASDAQ:CCCC) and lower its price target from $57.00 to $20.00.
Shares of C4 Therapeutics are trading down 20.49% over the last 24 hours, at $9.00 per share.
Why C4 Therapeutics Stock Is Plunging Today
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455.
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma Trial
C4 Therapeutics Inc (NASDAQ: CCCC) has presented data from Cohort A of its ongoing Phase 1/2 trial of CFT7455 for multiple myeloma (MM) and non-Hodgkin's lymphomas (NHL).
28 Stocks Moving In Friday’s Mid-Day Session
Gainers
Lyra Therapeutics, Inc. (NASDAQ: LYRA) shares climbed 33.3% to $5.78 as the company reported a private placement for gross proceeds of $110.5 million.
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
C4 Therapeutics Halted On Circuit Breaker Following Co. Press Release Highlighting Presentation Of Data From Cohort A Of Ongoing Phase 1/2 Trial Of Its CFT7455
– Single Agent CFT7455 Induces Deep and Durable Degradation of IKZF1/3 and Meaningful Decreases in Serum Free Light Chain at Doses Lower than Expected Based on Pre-clinical Studies –
– CFT7455 Exhibits
51 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares surged 148.2% to close at $5.61 on Tuesday after the company announced that two of its designed mRNA molecules are effective at destroying cancer cells grown in culture.
87 Biggest Movers From Yesterday
Gainers
Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to Nasdaq at $4.25 per unit.